Penumbra Inc (PEN)

Currency in USD
255.99
-0.07(-0.03%)
Real-time Data·
PEN Scorecard
Full Analysis
Net income is expected to grow this year
PEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
253.70260.42
52 wk Range
190.08310.00
Key Statistics
Prev. Close
256.06
Open
258.45
Day's Range
253.7-260.42
52 wk Range
190.08-310
Volume
98.21K
Average Volume (3m)
461.57K
1-Year Change
31.49%
Book Value / Share
33.41
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PEN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
303.33
Upside
+18.49%
Members' Sentiments
Bearish
Bullish
ProTips
14 analysts have revised their earnings downwards for the upcoming period

Penumbra Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

Penumbra Inc Company Profile

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Penumbra Inc SWOT Analysis


Market Dominance
Penumbra's strong performance in the U.S. VTE market, with 42% year-over-year growth, signals potential for significant market share gains and expansion
Innovation Pipeline
Explore Penumbra's product developments, including Thunderbolt and Lightning Flash 2.0, poised to drive growth and solidify market position
Financial Outlook
Analysts project double-digit revenue growth and margin expansion, with price targets ranging from $232 to $330, reflecting optimism in Penumbra's prospects
Challenges Ahead
Delve into Penumbra's strategic approach to overcoming China market headwinds and potential operational hurdles while maintaining a conservative growth outlook
Read full SWOT analysis

Penumbra Inc Earnings Call Summary for Q2/2025

  • Penumbra Inc. beats Q2 2025 estimates with EPS of $0.86 and revenue of $339.5M, up 13.4% YoY
  • Full-year revenue guidance raised to $1.355B-$1.370B, projecting 13-15% growth
  • U.S. sales grew 19.5%, while international sales declined 3.2%; gross margin at 66% with 70%+ target by 2026
  • CEO highlights market share gains in DVT and PE markets; company maintains strong financial health with no debt
  • Stock fell 1.31% despite positive earnings, closing at $230.17; company expects continued growth in thrombectomy market
Last Updated: 29/07/2025, 22:58
Read Full Transcript

Compare PEN to Peers and Sector

Metrics to compare
PEN
Peers
Sector
Relationship
P/E Ratio
67.3x−20.2x−0.7x
PEG Ratio
0.071.050.00
Price/Book
7.7x3.5x2.6x
Price / LTM Sales
7.8x1.9x3.4x
Upside (Analyst Target)
24.0%9.3%36.2%
Fair Value Upside
Unlock−14.7%4.1%Unlock

Analyst Ratings

15 Buy
4 Hold
1 Sell
Ratings:
20 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 303.33
(+18.49% Upside)

Earnings

Latest Release
Jul 29, 2025
EPS / Forecast
0.86 / 0.83
Revenue / Forecast
339.50M / 327.77M
EPS Revisions
Last 90 days

PEN Income Statement

People Also Watch

40.19
EXEL
+0.25%
397.41
BLD
-0.50%
675.58
EME
+3.24%
230.72
ALAB
+14.93%
205.95
IQV
-0.33%

FAQ

What Stock Exchange Does Penumbra Inc Trade On?

Penumbra Inc is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Penumbra Inc?

The stock symbol for Penumbra Inc is "PEN."

What Is the Penumbra Inc Market Cap?

As of today, Penumbra Inc market cap is 9.94B.

What Is Penumbra Inc's Earnings Per Share (TTM)?

The Penumbra Inc EPS (TTM) is 3.74.

When Is the Next Penumbra Inc Earnings Date?

Penumbra Inc will release its next earnings report on 28 Oct 2025.

From a Technical Analysis Perspective, Is PEN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Penumbra Inc Stock Split?

Penumbra Inc has split 0 times.

How Many Employees Does Penumbra Inc Have?

Penumbra Inc has 4500 employees.

What is the current trading status of Penumbra Inc (PEN)?

As of 06 Oct 2025, Penumbra Inc (PEN) is trading at a price of 255.99, with a previous close of 256.06. The stock has fluctuated within a day range of 253.70 to 260.42, while its 52-week range spans from 190.08 to 310.00.

What Is Penumbra Inc (PEN) Price Target According to Analysts?

The average 12-month price target for Penumbra Inc is USD303.33333, with a high estimate of USD350 and a low estimate of USD186. 15 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +18.49% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.